Skip to main content
Presentation
Long-term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1). Spanish Society of Rheumatology (SER), Bilbao, Spain, May 2017.
Spanish Society of Rheumatology (SER) (2017)
  • A Kavanaugh
  • DD Gladman
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
May, 2017
Citation Information
A Kavanaugh, DD Gladman, Philip Mease and et.al.. "Long-term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1). Spanish Society of Rheumatology (SER), Bilbao, Spain, May 2017." Spanish Society of Rheumatology (SER) (2017)
Available at: http://works.bepress.com/philip-mease/262/